New research suggests that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who end traditional diet and exercise regimens.
Published data in a leading health publication demonstrates that while overweight people can lose about a fifth of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People using these medications must be aware of the potential of fast weight regain when the medication concludes," cautioned expert Dr. Susan Jebb.
This pace of regain suggests a return to original weight in about one and a half years.
Comparing Approaches
The analysis, which examined dozens of trials involving thousands of patients, compared the effects of these new drugs with conventional dieting.
Scientists point out that individuals who lose weight through diet and exercise generally see a slower creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Nutrition scientists propose the mechanism of the jabs is key to understanding the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of the hormone concentrations far above than normal might result in the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
Health authorities advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the treatment is often long-term.
This opinion is supported by drug manufacturers, who say that the findings "underscore the long-term nature of obesity," akin to managing conditions like diabetes.
User Experiences
Individuals who have come off the jabs explain a sudden return of cravings.
"It felt as if a switch that goes on and I was suddenly ravenous," recalled an individual.
This challenge is exacerbated if individuals have not established lasting dietary or behavioural changes during treatment.
Significant Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts emphasize that while these medications are effective tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on ongoing lifestyle support.
